---

$3.23

+0.3900 ( +16.19% ) 292.5K

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

Analyst Insights

---

You need to login to view this content.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-12-18	Buy	40000.00	Javitt Jonathan C
2023-09-11	Buy	70000.00	Hurvitz Chaim
2023-09-11	Buy	35000.00	Gorovitz Aaron
2023-08-24	Buy	100000.00	Javitt Jonathan C
2023-08-23	Buy	200000.00	Javitt Jonathan C

Reset

Symbol	Issuer Name	Market Value ↓	Share Quantity
No records found.